Prof. Hong Yang, Sun Yat-sen University Cancer Center, China
Prof. Sai-Hong Ignatius Ou, School of Medicine, University of California, Irvine, USA
Prof. Yang and Prof. Ou discussed perioperative and adjuvant treatment strategies for resectable ALK-positive NSCLC, with a focus on whether lorlatinib should be introduced earlier in treatment. They also explored the role of neoadjuvant/adjuvant ALK TKI trials, the comparison between lorlatinib and second-generation ALK TKIs, the optimal duration of adjuvant therapy, and the current limitations of MRD-guided treatment de-escalation.